Us China Asthma Copd Drugs Market

Asthma and COPD Drugs Market (Drug Class - Bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies, and Combination Drugs; Indication - Asthma and COPD) - U.S. and China Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • Rep Id : TMRGL15857
  • Published On : Oct 2016
  • No. of Pages : 101
  • Category : Pharmaceutical

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: U.S. and China Asthma and COPD Drugs Market

Chapter 4. Market Overview
4.1. Introduction 
4.2. Key Industry Developments
4.3. Market Dynamics
      4.3.1. Drivers
      4.3.2. Restraints
      4.3.3. Opportunity
4.4. Porter’s Five Forces Analysis

Chapter 5. U.S. and China Asthma and COPD Drugs Market Analysis and Forecast, By Drug Class
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Drug Class
      5.3.1. Bronchodilators
               5.3.1.1. Short Acting Beta-2 Agonists 
               5.3.1.2. Long Acting Beta-2 Agonists
               5.3.1.3. Anti-cholinergic Agents 
      5.3.2. Anti-inflammatory Drugs
               5.3.2.1. Oral and Inhaled Corticosteroids
               5.3.2.2. Anti-leukotrienes
               5.3.2.3. Phosphodiesterase Type-4 Inhibitors
               5.3.2.4. Others
      5.3.3. Monoclonal Antibodies
      5.3.4. Combination Drugs
5.4. Market Attractiveness Analysis, by Drug Class, 2015
5.5. Key Trends

Chapter 6. U.S. and China Asthma and COPD Drugs Market Analysis and Forecast, By Indication
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Indication
      6.3.1. Asthma
      6.3.2. COPD
6.4. Market Attractiveness Analysis, by Indication, 2015
6.5. Key Trends

Chapter 7. U.S. and China Asthma and COPD Drugs Market Analysis and Forecast, By Region
7.1. Market Scenario
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Region
      7.3.1. U.S.
      7.3.2. China
7.4. Market Attractiveness Analysis, by Region, 2015

Chapter 8. U.S. Asthma and COPD Drugs Market Analysis and Forecast 
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast, by Drug Class
      8.3.1. Bronchodilators
               8.3.1.1. Short Acting Beta-2 Agonists 
               8.3.1.2. Long Acting Beta-2 Agonists
               8.3.1.3. Anti-cholinergic Agents 
      8.3.2. Anti-inflammatory Drugs
               8.3.2.1. Oral and Inhaled Corticosteroids
               8.3.2.2. Anti-leukotrienes
               8.3.2.3. Phosphodiesterase Type-4 Inhibitors
               8.3.2.4. Others
      8.3.3. Monoclonal Antibodies
      8.3.4. Combination Drugs
8.4. Market Size (US$ Mn) Forecast, by Indication
      8.4.1. Asthma
      8.4.2. COPD
      8.4.3. Canada
8.5. Market Attractiveness Analysis, by Drug Class, 2015
8.6. Market Attractiveness Analysis, by Indication, 2015
8.7. Key Trends

Chapter 9. China Asthma and COPD Drugs Market Analysis and Forecast 
9.1. Key Findings
9.2. Introduction
9.3. Market Size (US$ Mn) Forecast, by Drug Class
      9.3.1. Bronchodilators
               9.3.1.1. Short Acting Beta-2 Agonists 
               9.3.1.2. Long Acting Beta-2 Agonists
               9.3.1.3. Anti-cholinergic Agents 
      9.3.2. Anti-inflammatory Drugs
               9.3.2.1. Oral and Inhaled Corticosteroids
               9.3.2.2. Anti-leukotrienes
               9.3.2.3. Phosphodiesterase Type-4 Inhibitors
               9.3.2.4. Others
      9.3.3. Monoclonal Antibodies
      9.3.4. Combination Drugs
9.4. Market Size (US$ Mn) Forecast, by Indication
      9.4.1. Asthma
      9.4.2. COPD
      9.4.3. Canada
9.5. Market Attractiveness Analysis, by Drug Class, 2015
9.6. Market Attractiveness Analysis, by Indication, 2015
9.7. Key Trends

Chapter 10. Competition Landscape
10.1. Global Asthma and COPD Drugs Market Share Analysis, Key Players, 2015
10.2. Competition Matrix
10.3. Company Profiles
      10.3.1. AstraZeneca plc
               10.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
               10.3.1.2. Financial Overview
               10.3.1.3. Product Portfolio
               10.3.1.4. SWOT Analysis
               10.3.1.5. Strategic Overview
      10.3.2. Boehringer Ingelheim GmbH
               10.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
               10.3.2.2. Financial Overview
               10.3.2.3. Product Portfolio
               10.3.2.4. SWOT Analysis
               10.3.2.5. Strategic Overview
      10.3.3. F Hoffmann-La Roche Ltd.
               10.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
               10.3.3.2. Financial Overview
               10.3.3.3. Product Portfolio
               10.3.3.4. SWOT Analysis
      10.3.4. GlaxoSmithKline plc
               10.3.4.1. Company Overview (HQ, business segments, employee strength)
               10.3.4.2. Financial Overview
               10.3.4.3. Product Portfolio
               10.3.4.4. SWOT Analysis
               10.3.4.5. Strategic Overview
      10.3.5. Merck & Co., Inc.
               10.3.5.1. Company Overview (HQ, business segments, employee strength)
               10.3.5.2. Product Portfolio
               10.3.5.3. SWOT Analysis
               10.3.5.4. Recent Developments
               10.3.5.5. Strategic Overview
      10.3.6. Novartis AG
               10.3.6.1. Company Overview (HQ, business segments, employee strength)
               10.3.6.2. Financial Overview
               10.3.6.3. Product Portfolio
               10.3.6.4. SWOT Analysis
               10.3.6.5. Strategic Overview

List of Tables

Table 1: U.S. and China Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Drug Class, 2014–2024
Table 2: U.S. and China Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Indication, 2014–2024
Table 3: U.S. and China Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Region, 2014–2024
Table 4: U.S. Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Drug Class, 2014–2024
Table 5: U.S. Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Indication Type, 2014–2024
Table 6: China Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Drug Class, 2014–2024
Table 7: China Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Indication, 2014–2024

List of Figures

Figure 1: U.S. and China Asthma and COPD Drugs Market Size (US$ Mn), 2014–2024
Figure 2: U.S. and China Asthma and COPD Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 3: U.S. and China Bronchodilators Market Revenue (US$ Mn), 2014–2024
Figure 4: U.S. and China Anti-inflammatory Drugs Market Revenue (US$ Mn), 2014–2024
Figure 5: U.S. and China Monoclonal Antibodies Market Revenue (US$ Mn), 2014–2024
Figure 6: U.S. and China Combination Drugs Market Revenue (US$ Mn), 2014–2024
Figure 7: U.S. and China Asthma and COPD Drugs Attractiveness Analysis, by Drug Class, 2015
Figure 8: U.S. and China Asthma and COPD Drugs Value Share Analysis, by Indication, 2016 and 2024
Figure 9: U.S. and China Asthma Market Revenue (US$ Mn), 2014–2024
Figure 10: U.S. and China COPD Market Revenue (US$ Mn), 2014–2024
Figure 11: U.S. and China Asthma and COPD Drugs Attractiveness Analysis, by Indication, 2015
Figure 12: Global U.S. and China Asthma and COPD Drugs Value Share Analysis, by Region, 2016 and 2024
Figure 13: U.S. and China Asthma and COPD Drugs Attractiveness Analysis, by Region, 2015
Figure 14: U.S. Asthma and COPD Drugs Market Size (US$ Mn), 2014–2024
Figure 15: U.S. Asthma and COPD Drugs Market Y-o-Y Growth Projections, 2015–2024
Figure 16: U.S. Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 17: U.S. Market Value Share Analysis, by Indication, 2016 and 2024
Figure 18: U.S. Asthma and COPD Drugs Market Analysis and Forecast, US$ Mn, by Drug Class, 2014–2024
Figure 19: U.S. Asthma and COPD Drugs Market Analysis and Forecast, US$ Mn, by Indication, 2014–2024
Figure 20: U.S. Asthma and COPD Drugs Market Attractiveness Analysis, by Drug Class, 2015
Figure 21: U.S. Asthma and COPD Drugs Market Attractiveness Analysis, by Indication, 2015
Figure 22: China Asthma and COPD Drugs Market Size (US$ Mn), 2014–2024
Figure 23: China Asthma and COPD Drugs Market Y-o-Y Growth Projections, 2015–2024
Figure 24: China Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 25: China Market Value Share Analysis, by Indication, 2016 and 2024
Figure 26: China Asthma and COPD Drugs Market Analysis and Forecast, US$ Mn, by Drug Class, 2014–2024
Figure 27: China Asthma and COPD Drugs Market Analysis and Forecast, US$ Mn, by Indication, 2014–2024
Figure 28: China Asthma and COPD Drugs Market Attractiveness Analysis, by Drug Class, 2015
Figure 29: China Asthma and COPD Drugs Market Attractiveness Analysis, by Indication, 2015
Figure 30: Global Asthma and COPD Drugs Market Share Analysis, by Company (2015)